The target audience for this activity is physicians, pharmacists, and other healthcare professionals caring for patients with suspected or documented antimicrobial resistant nosocomial pneumonia.
The goal of this activity is to improve the knowledge and competence of healthcare professionals in improving antimicrobial management of HAP/VAP and outcomes for patients with suspected or documented antimicrobial resistance.
Upon completion of this activity, participants should be able to:
Assess phenotypic susceptibility patterns and molecular resistance of gram-negative pathogens to determine appropriate antimicrobial therapy
Compare available antimicrobial agents for HAP/VAP caused by difficult-to-treat gram-negative pathogens
Incorporate guidelines, patient-specific factors, and laboratory data into the selection of optimal treatment regimens for patients with known or suspected antimicrobial-resistant gram-negative infections
ProCE, LLC and Clinical Care Options, LLC (CCO) require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE and CCO policy. ProCE and CCO are committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Kayla R. Stover Hielscher, PharmD, BCIDP, BCPS, FCCP, FIDSA
Professor of Pharmacy Practice
Program Director, PGY2 Infectious Diseases Residency
University of Mississippi Medical Center
Kayla Stover, PharmD, FISA, FCCP, BCIDP, BCPS: consultant/advisor/speaker: Cidara Therapeutics.
Trevor Van Schooneveld, MD, FSHEA, FACP
Professor, Division of Infectious Diseases
Program Director, Infectious Diseases Fellowship
Medical Director, Antimicrobial Stewardship Program
University of Nebraska Medical Center
Trevor Van Schooneveld, MD, FSHEA, FACP: consultant/advisor/speaker: bioMérieux, Thermo Fisher; researcher: AN2 Therapeutics, Insmed.
The planners and content peer reviewers from ProCE, LLC, Clinical Care Options, LLC and the SIDP do not have any relevant financial relationships to disclose.
Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 14, 2023, through June 13, 2024:
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO), ProCE, LLC and Society of Infectious Diseases Pharmacists (SIDP). Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
This activity is jointly provided by ProCE, LLC, Clinical Care Options, LLC, and the Society of Infectious Diseases Pharmacists (SIDP). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-23-014-H01-P has been assigned to this home study application-based activity. This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. This activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 65 or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.